Advertisement


Matt D. Galsky, MD, on Bladder Cancer: Neoadjuvant Therapy With Gemcitabine, Cisplatin, and Nivolumab

2021 ASCO Annual Meeting

Advertisement

Matt D. Galsky, MD, of the Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, discusses results from a phase II trial designed to test gemcitabine and cisplatin plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to better predict benefit in those who opted out of cystectomy (Abstract 4503).



Related Videos

Lung Cancer
Genomics/Genetics
Immunotherapy

Pasi A. Janne, MD, PhD, on NSCLC: Patritumab Deruxtecan to Target HER3

Pasi A. Janne, MD, PhD, of Dana-Farber Cancer Institute, discusses study findings that show patritumab deruxtecan is effective in patients with EGFR-mutated and inhibitor-resistant non–small cell lung cancer. Dr. Janne also explains why targeting HER3, a mutation expressed in most EGFR-altered cancers, is a beneficial treatment approach (Abstract 9007).

Multiple Myeloma

Taiga Nishihori, MD, on Multiple Myeloma: Maintenance Ixazomib After Transplant

Taiga Nishihori, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the outcome of a trial that explored maintenance therapy with ixazomib after allogeneic hematopoietic cell transplantation in patients with high-risk multiple myeloma. Toxicities unrelated to the maintenance treatment forced the trial to close prematurely (Abstract 7003).

Skin Cancer
Immunotherapy

Evan J. Lipson, MD, on Melanoma: Relatlimab and Nivolumab in First-Line Treatment of Advanced Disease

Evan J. Lipson, MD, of Johns Hopkins University, discusses primary phase III results from the RELATIVITY-047 study, which showed that relatlimab plus nivolumab as a fixed-dose combination may improve progression-free survival compared with nivolumab monotherapy in patients with advanced melanoma. This is the first study to demonstrate a benefit from dual inhibition of the LAG-3 and PD-1 pathways.

Lymphoma

Brian K. Link, MD, on Mantle Cell Lymphoma: Expert Perspective on Treatments Now and Those to Come

Brian K. Link, MD, of the University of Iowa Carver College of Medicine, reviews three abstracts on state-of-the-art therapies for mantle cell lymphoma: bendamustine, rituximab, lenalidomide and bortezomib; treatment patterns and outcomes for previously untreated patients; and venetoclax, lenalidomide, and rituximab in newly diagnosed disease (Abstracts 7503, 7504, and 7505).

Bladder Cancer

Sumanta K. Pal, MD, on Urothelial Carcinoma: Comparing Cisplatin and Gemcitabine With or Without Berzosertib

Sumanta K. Pal, MD, of City of Hope, discusses results from a phase II study that sought to determine whether adding berzosertib, a selective ATR inhibitor, to the standard upfront chemotherapy regimen of cisplatin with gemcitabine may improve outcomes in patients with metastatic urothelial carcinoma (Abstract 4507).

Advertisement

Advertisement




Advertisement